Pheochromocytoma: The range of appearances on ultrasound, CT, MRI, and functional imaging

American Journal of Roentgenology

Volumn 200, Issue 2, 2013, Pages 370-378

  Leung, Katherine ^a   Stamm, Michael ^a   Raja, Asim ^a   Low, Gavin ^a  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

Adrenal gland neoplasms; MDCT; MRI; Pheochromocytomas; Radionuclide imaging; Sonography

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 6 FLUORODOPA F 18; 6 FLUORODOPAMINE F 18; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DACARBAZINE; FLUORODEOXYGLUCOSE F 18; PENTETREOTIDE IN 111; VINCRISTINE;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL LYMPHOMA; ADRENAL METASTASIS; ADRENALECTOMY; BIOCHEMISTRY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; GENE; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; LAPAROSCOPIC SURGERY; LYMPHOMA; MULTIPLE ENDOCRINE NEOPLASIA; NEUROBLASTOMA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RET GENE; REVIEW; SDHB GENE; SDHD GENE; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SIPPLE SYNDROME; TUMOR DIFFERENTIATION; VHL GENE; VON HIPPEL LINDAU DISEASE;

ADRENAL GLAND NEOPLASMS; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; HUMANS; NEOPLASM STAGING; PHEOCHROMOCYTOMA; PREVALENCE;

EID: 84873608247     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.12.9126     Document Type: Review

References (74)

1. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005; 366:665-675
2. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287:1427-1434
3. Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 1994; 12:609-615
4. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004; 27:193-202
5. Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JW. Secondary hypertension in a blood pressure clinic. Arch Intern Med 1987; 147:1289-1293
6. McNeil AR, Blok BH, Koelmeyer TD, Burke MP, Hilton JM. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust N Z J Med 2000; 30:648-652
7. Stenström G, Svärdsudd K. Pheochromocytoma in Sweden 1958-1981: an analysis of the National Cancer Registry Data. Acta Med Scand 1986; 220:225-232
8. Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002; 346:1459-1466
9. Pham TH, Moir C, Thompson GB, et al. Pheochromocytoma and paraganglioma in children: a review of medical and surgical management at a tertiary care center. Pediatrics 2006; 118:1109-1117
10. Mannelli M, Ianni L, Cilotti A, Conti A. Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol 1999; 141:619-624
11. Elder EE, Elder G, Larsson C. Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% rule. J Surg Oncol 2005; 89:193-201
12. Renard J, Clerici T, Licker M, Triponez F. Pheochromocytoma and abdominal paraganglioma. J Visc Surg 2011; 148:e409-e416
13. Neumann HP, Berger DP, Sigmund G, et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993; 329:1531-1538
14. Walther MM, Reiter R, Keiser HR, et al. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol 1999; 162:659-664
15. Modigliani E, Vasen HM, Raue K, et al. Pheochromocytoma in multiple endocrine neoplasia type 2: European study - The Euromen Study Group. J Intern Med 1995; 238:363-367
16. Dluhy RG. Pheochromocytoma: death of an axiom. N Engl J Med 2002; 346:1486-1488
17. Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004; 292:943-951
18. Kopetschke R, Slisko M, Kilisli A, et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol 2009; 161:355-361
19. Proye C, Fossati P, Fontaine P, et al. Dopaminesecreting pheochromocytoma: an unrecognized entity? Classification of pheochromocytomas according to their type of secretion. Surgery 1986; 100:1154-1162
20. Bergland BE. Pheochromocytoma presenting as shock. Am J Emerg Med 1989; 7:44-48
21. Aso Y, Homma Y. A survey on incidental adrenal tumors in Japan. J Urol 1992; 147:1478-1481
22. Baguet JP, Hammer L, Mazzuco TL, et al. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol 2004; 150:681-686
23. Motta-Ramirez GA, Remer EM, Herts BR, Gill IS, Hamrahian AH. Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas. AJR 2005; 185:684-688
24. Raisanen J, Shapiro B, Glazer GM, Desai S, Sisson JC. Plasma catecholamines in pheochromocytoma: effect of urographic contrast media. AJR 1984; 143:43-46
25. Mukherjee JJ, Peppercorn PD, Reznek RH, et al. Pheochromocytoma: effect of nonionic contrast medium in CT on circulating catecholamine levels. Radiology 1997; 202:227-231
26. Bessell-Browne R, O'Malley ME. CT of pheochromocytoma and paraganglioma: risk of ad- verse events with IV administration of nonionic contrast material. AJR 2007; 188:970-974
27. American College of Radiology (ACR) website. ACR Committee on Drugs and Contrast Media. Patient selection and preparation strategies. In: ACR manual on contrast media, version 7. www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/ Resources/Contrast%20Manual/FullManual.pdf. Published 2010. Accessed May 28, 2012
28. Chen H, Sippel RS, O'Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010; 39:775-783
29. John H, Ziegler WH, Hauri D, Jaeger P. Pheochromocytomas: can malignant potential be predicted? Urology 1999; 53:679-683
30. Havekes B, Lai EW, Corssmit EP, Romijn JA, Timmers HJ, Pacak K. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging. Q J Nucl Med Mol Imaging 2008; 52:419-429
31. Ilias I, Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 2004; 89:479-491
32. Beierwaltes WH. Endocrine imaging: parathyroid, adrenal cortex and medulla, and other endocrine tumors: part II. J Nucl Med 1991; 32:1627-1639
33. Lenders JW, Keiser HR, Goldstein DS, et al. Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med 1995; 123:101-109
34. Maitra A. The endocrine system. In: Kumar V, Abbas A, Fausto N, Aster J, eds. Robbins and Cotran pathologic basis of disease, professional edition: expert consult, 8th ed. Philadelphia, PA: Saunders Elsevier, 2010:1159-1161
35. Thompson LD. Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 2002; 26:551-566
36. Agarwal A, Mehrotra PK, Jain M, et al. Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy? World J Surg 2010; 34:3022-3028
37. Jacques AE, Sahdev A, Sandrasagara M, et al. Adrenal phaeochromocytoma: correlation of MRI appearances with histology and function. Eur Radiol 2008; 18:2885-2892
38. Bowerman RA, Silver TM, Jaffe MH, Stuck KJ, Hinerman DL. Sonography of adrenal pheochromocytomas. AJR 1981; 137:1227-1231
39. Park BK, Kim CK, Kwon GY, Kim JH. Re-evaluation of pheochromocytomas on delayed contrastenhanced CT: washout enhancement and other imaging features. Eur Radiol 2007; 17:2804-2809
40. Blake MA, Krishnamoorthy SK, Boland GW, et al. Low-density pheochromocytoma on CT: a mimicker of adrenal adenoma. AJR 2003; 181:1663-1668
41. Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR 1998; 171:201-204
42. Szolar DH, Kammerhuber FH. Adrenal adenomas and nonadenomas: assessment of washout at delayed contrast-enhanced CT. Radiology 1998; 207:369-375
43. Szolar DH, Korobkin M, Reittner P, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology 2005; 234:479-485
44. Elsayes KM, Mukundan G, Narra VR, et al. Adrenal masses: MR imaging features with pathologic correlation. RadioGraphics 2004; 24(suppl 1):S73-S86
45. Varghese JC, Hahn PF, Papanicolaou N, Mayo-Smith WW, Gaa JA, Lee MJ. MR differentiation of phaeochromocytoma from other adrenal lesions based on qualitative analysis of T2 relaxation times. Clin Radiol 1997; 52:603-606
46. Blake MA, Kalra MK, Maher MM, et al. Pheochromocytoma: an imaging chameleon. Radio-Graphics 2004; 24(suppl 1):S87-S99
47. Krestin GP, Steinbrich W, Friedmann G. Adrenal masses: evaluation with fast gradient-echo MR imaging and Gd-DTPA-enhanced dynamic studies. Radiology 1989; 171:675-680
48. Lumachi F, Tregnaghi A, Zucchetta P, et al. Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas: a prospective study. Nucl Med Commun 2006; 27:583-587
49. Nakatani T, Hayama T, Uchida J, Nakamura K, Takemoto Y, Sugimura K. Diagnostic localization of extra-adrenal pheochromocytoma: comparison of (123)I-MIBG imaging and (131)I-MIBG imaging. Oncol Rep 2002; 9:1225-1227
50. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992; 13:513-521
51. Meyer-Rochow GY, Schembri GP, Benn DE, et al. The utility of metaiodobenzylguanidine single photon emission computed tomography/computed tomography (MIBG SPECT/CT) for the diagnosis of pheochromocytoma. Ann Surg Oncol 2010; 17:392-400
52. Rozovsky K, Koplewitz BZ, Krausz Y, et al. Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. AJR 2008; 190:1085-1090
53. van der Harst E, de Herder WW, Bruining HA, et al. [(123)I] metaiodobenzylguanidine and [(111) In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001; 86:685-693
54. Hoefnagel CA. MIBG and radiolabeled octreotide in neuroendocrine tumors. Q J Nucl Med 1995; 39:137-139
55. Hoegerle S, Nitzsche E, Altehoefer C, et al. Pheochromocytomas: detection with 18F DOPA whole body PET - initial results. Radiology 2002; 222:507-512
56. Ilias I, Yu J, Carrasquillo JA, et al. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]- metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 2003; 88:4083-4087
57. Hovevey-Sion D, Eisenhofer G, Kopin IJ, et al. Metabolic fate of injected radiolabelled dopamine and 2-fluorodopamine in rats. Neuropharmacology 1990; 29:881-887
58. Kauhanen S, Seppänen M, Ovaska J, et al. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer 2009; 16:255-265
59. Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS. 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 2001; 38:6-8
60. Boland GW, Dwamena BA, Jagtiani Sangwaiya M, et al. Characterization of adrenal masses by using FDG PET: a systematic review and metaanalysis of diagnostic test performance. Radiology 2011; 259:117-126
61. Taïeb D, Sebag F, Barlier A, et al. 18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature? J Nucl Med 2009; 50:711-717
62. Johnson PT, Horton KM, Fishman EK. Adrenal mass imaging with multidetector CT: pathologic conditions, pearls, and pitfalls. RadioGraphics 2009; 29:1333-1351
63. Peña CS, Boland GW, Hahn PF, Lee MJ, Mueller PR. Characterization of indeterminate (lipidpoor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology 2000; 217:798-802
64. Korobkin M, Giordano TJ, Brodeur FJ, et al. Adrenal adenomas: relationship between histologic lipid and CT and MR findings. Radiology 1996; 200:743-747
65. Wajchenberg BL, Albergaria Pereira MA, Medonca BB, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000; 88:711-736
66. Smith SM, Patel SK, Turner DA, Matalon TA. Magnetic resonance imaging of adrenal cortical carcinoma. Urol Radiol 1989; 11:1-6
67. Lonergan GJ, Schwab CM, Suarez ES, Carlson CL. Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation. RadioGraphics 2002; 22:911-934
68. Abrams HL, Spiros R, Goldstein N. Metastases in carcinoma: analysis of 1000 autopsied cases. Cancer 1950; 3:74-85
69. Zhou L, Peng W, Wang C, Liu X, Shen Y, Zhou K. Primary adrenal lymphoma: radiological, pathological, clinical correlation. Eur J Radiol 2012; 81:401-405
70. Dickson PV, Alex GC, Grubbs EG, et al. Posterior retroperitoneoscopic adrenalectomy is a safe and effective alternative to transabdominal laparoscopic adrenalectomy for pheochromocytoma. Surgery 2011; 150:452-458
71. Grogan RH, Mitmaker EJ, Duh QY. Changing paradigms in the treatment of malignant pheochromocytoma. Cancer Control 2011; 18:104-112
72. Shapiro B, Gross MD, Shulkin B. Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends Endocrinol Metab 2001; 12:469-475
73. Khorram-Manesh A, Ahlman H, Nilsson O, et al. Long-term outcome of a large series of patients surgically treated for pheochromocytoma. J Intern Med 2005; 258:55-66
74. Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G, Plouin PF. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 2005; 90:2110-2116